Efficacy and Safety of Continuous Fingolimod Treatment for At Least 5 Years in Patients with Relapsing-remitting Multiple Sclerosis: Analysis of Long-term Data

L. Kappos, N. Tenenbaum, A. Bhatt, A. Couturier, J. Cohen